RPL17 and neoplasm: Blocking immune checkpoint molecules, including the CTLA4, PD-1, and PD-L1 molecules, was proposed as a highly effective anti-tumor treatment for most types of cancer (1, 2), with a 20%–50% success rate in different clinical trials (3).